<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355689</url>
  </required_header>
  <id_info>
    <org_study_id>C-18-04</org_study_id>
    <nct_id>NCT04355689</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome</brief_title>
  <acronym>SLO RP</acronym>
  <official_title>Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nacuity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Fighting Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nacuity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for&#xD;
      24 months in subjects with vision loss due to RP associated with Usher syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the safety and efficacy of oral NPI-001 Tablets as compared to oral&#xD;
      placebo tablets for 24 months in subjects with vision loss due to RP associated with Usher&#xD;
      syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>NPI-001 Tablets versus Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Usher Syndromes</condition>
  <arm_group>
    <arm_group_label>NPI-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NPI-001 Tablet, 250 mg, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tablet, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPI-001</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>NPI-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age ≥18 years.&#xD;
&#xD;
          2. Able to comprehend and willing to sign an informed consent form (ICF) and to adhere to&#xD;
             the study protocol.&#xD;
&#xD;
          3. Diagnosed with Usher syndrome.&#xD;
&#xD;
          4. EZ zone with width ≥500 microns, which includes the fovea in each eye at Visit 2,&#xD;
             (Screen B).&#xD;
&#xD;
          5. Have at least 20 detectable points on the MAIA grid.&#xD;
&#xD;
          6. On stable dose of medications associated with other conditions for at least one month.&#xD;
&#xD;
          7. Both female participants of childbearing potential and male participants able to&#xD;
             father children must have (or have a partner who has) had a bilateral oophorectomy,&#xD;
             hysterectomy or bilateral salpingectomy; must abstain from intercourse; or must agree&#xD;
             to practice 2 acceptable methods of contraception throughout the course of the study&#xD;
             and 4 weeks after the last visit. Acceptable methods of contraception include hormonal&#xD;
             contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal&#xD;
             ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, tubal&#xD;
             ligation, or vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ocular:&#xD;
&#xD;
          1. All edges of the EZ area in both eyes cannot be visualized at Visit 2 (Screen B).&#xD;
&#xD;
          2. Concurrent retinal pathologies that result in vision loss or inability to fixate,&#xD;
             including but not limited to, choroideremia, retinal vein occlusion, and neovascular&#xD;
             age-related macular degeneration.&#xD;
&#xD;
          3. Intraocular surgery within the last two months or capsulotomy within the last month.&#xD;
&#xD;
          4. History of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of&#xD;
             the eye, or currently has a cataract that prevents visualization of the posterior&#xD;
             pole.&#xD;
&#xD;
          5. Unstable fixation during microperimetry in either eye at either screening or baseline&#xD;
             visits.&#xD;
&#xD;
             Non-Ocular:&#xD;
&#xD;
          6. Use of any other investigational new drug, or participation in another clinical trial&#xD;
             within 12 weeks before the start of study treatment.&#xD;
&#xD;
          7. Use of N-acetylcysteine containing products in the previous 30 days prior to the&#xD;
             baseline visit or unwilling to refrain from such supplements for the duration of the&#xD;
             study.&#xD;
&#xD;
          8. Liver or kidney disease, cystic fibrosis, asthma or chronic obstructive pulmonary&#xD;
             disease (COPD), history of thrombocytopenia not due to a reversible cause, or other&#xD;
             blood dyscrasia.&#xD;
&#xD;
          9. Suspected liver dysfunction determined by having alanine aminotransferase (ALT),&#xD;
             aspartate aminotransferase (AST), or bilirubin values &gt; 1.5 X the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
         10. Platelet or hemoglobin values that are below the lower limit of normal at screening&#xD;
             (subjects with normal hemoglobin and mean corpuscular volume below the lower limit of&#xD;
             normal should have iron studies performed to ensure that they are iron replete before&#xD;
             taking part in the study), or neutrophils or white cell count which is above the upper&#xD;
             limit of normal.&#xD;
&#xD;
         11. Presence of more than + proteinuria on urinalysis at screening or (confirmed by&#xD;
             abnormal albumin creatinine ratio).&#xD;
&#xD;
         12. Presence of hematuria on urinalysis at screening. (If hematuria is detected on&#xD;
             urinalysis, then the specimen should be subjected to microscopy, and subject should be&#xD;
             excluded if more than 10 X 106 red blood cells/L.) If the subject is a female in whom&#xD;
             the hematuria may be due to menses, then the urinalysis can be repeated after a few&#xD;
             days.&#xD;
&#xD;
         13. C-reactive protein (CRP) value above 10 mg/L.&#xD;
&#xD;
         14. Subject has a recent history of presence of gross blood in stools.&#xD;
&#xD;
         15. History of known sensitivity to N-acetylcysteine or similar thiol compounds.&#xD;
&#xD;
         16. History of hypersensitivity to any medication or food resulting in systemic symptoms.&#xD;
&#xD;
         17. History of cancer (other than non-melanoma skin cancer) diagnosed or requiring&#xD;
             treatment within the past 2 years.&#xD;
&#xD;
         18. Pregnant women or women planning to become pregnant in the next 25 months or men with&#xD;
             partners planning to become pregnant in the next 25 months.&#xD;
&#xD;
         19. Lactating women who are breast-feeding.&#xD;
&#xD;
         20. A potential participant lives in the same household as a current participant in this&#xD;
             study.&#xD;
&#xD;
         21. Inability to provide blood samples, including difficulty with venous access.&#xD;
&#xD;
         22. Any reason, in the opinion of the Principal Investigator, the subject should not&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Anderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nacuity Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jami Kern, PhD</last_name>
    <phone>+1-817-336-3000</phone>
    <email>info@nacuity.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>G. Michael Wall, PhD</last_name>
    <phone>+1-817-336-3000</phone>
    <email>info@nacuity.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queensland Eye Institute</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CERA</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney Eye Hospital / Save Sight Institute</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinitis pigmentosa Usher vision NPI-001 tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Usher Syndromes</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

